Visx leverages excimer laser patent position in non-U.S. licensing pact with Chiron.
This article was originally published in The Gray Sheet
Executive SummaryCHIRON VISION EXCIMER LASER NON-U.S. ROYALTY PAYMENTS TO VISX will be a "single digit" percentage of future unit sales under a patent license agreement signed the week of Sept. 25, Chiron reports. The agreement grants the Chiron subsidiary a worldwide license, excluding the U.S., for use of about 15 patents for laser vision correction that cover the fundamentals of ablation of tissue with ultraviolet light and the specific design of devices.
You may also be interested in...
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
The International Generic and Biosimilar Medicines Association has urged the World Intellectual Property Organization to withdraw its support for a global database of pharmaceutical patent information. The Pat-INFORMED database – which is comprised of intellectual-property information provided by originators – contains unverified data and lacks appropriate safeguards, the IGBA contends.
Reforms to the US 180-day exclusivity incentive included in the Blocking Act that is part of the Lower Health Care Costs Act could cost the US healthcare system approximately $1.7bn, the AAM has warned.